98760-27-1

Upstream product

• 3376-59-8 2,3-dihydroxypropyl benzoate 
• 67-64-1 acetone 
• 98-88-4 benzoyl chloride 
• 100-79-8 (R,S)-2,2-dimethyl-1,3-dioxolane-4-methanol 
• 582-25-2 Potassium benzoate 
• 4362-40-7 5-chloromethyl-2,2-dimethyl-1,3-dioxolane 
• 532-32-1 sodium benzoate 
• 93-58-3 benzoic acid methyl ester 
• 93-97-0 benzoic acid anhydride 
• 65-85-0 benzoic acid 

Downstream Products

• 4421-23-2 4-allyloxymethyl-2,2-dimethyl-1,3-dioxolane 
• 3376-59-8 2,3-dihydroxypropyl benzoate 
• 64904-47-8 2-benzoyloxyacetaldehyde 
• 111467-66-4 (S)-(-)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl benzoate 
• 22323-82-6 (S)-(+)-(2,2-dimethyl-[1,3]dioxolan-4-yl)methanol 
• 14347-78-5 1,2-O-isopropylidene-D-glycerol 
• 51432-60-1 (R)-(+)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl benzoate 
• 100-79-8 (R,S)-2,2-dimethyl-1,3-dioxolane-4-methanol 
• 143919-90-8 2-benzoyloxymethyl-5-acethoxy-1,3-oxathiolane 
• 358348-70-6 cis/trans-2-benzoyloxymethyl-5-(cytosin-1'-yl)-1,3-oxathiolane 
• 108636-60-8 3,4-cis-4-benzoyloxymethyl-3-benzyloxycarbonylamino-1-<(1S)-1-methoxycarbonyl-2-methylpropyl>-2-azetidinone 
• 918868-68-5 (+/-)-2-(mesyloxy)-3-[(4-methoxytrityl)oxy]propyl benzoate 

Relevant academic research and scientific papers

3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS

Compounds of formula (I) wherein Het1, Het2, R1, R2 and R3 are as defined in the description. Medicaments.

Synthesis of glycerolipids containing simple linear acyl chains or aromatic rings and evaluation of their Mincle signaling activity

Mincle, expressed in activated phagocytes, recognizes the lipid ligand to activate the innate immune system. We have synthesized glycerol derivatives possessing simple alkyl chains or aromatic rings and elucidated their structure-activity relationships us

Preparation method for emtricitabine isomer

The invention discloses a preparation method for an embritabine isomer. The preparation method comprises the following steps: with Solketal as a starting material, allowing the Solketal to undergo a six-step reaction of esterification, hydrolysis, oxidation, condensation cyclization, acetylation and glycosylation condensation so as to synthesize four mixture intermediates of emtricitabine; and splitting the four isomer intermediates into a cis-isomer mixture and a trans-isomer mixture through a chiral reagent. According to the invention, by adoption of a simple starting material, a mixture forsplitting key intermediates of four optical isomers of the emtricitabine is synthesized through the six-step reaction, and chiral acid is utilized to split the four isomers into a mixture of cis andtrans isomers, so the preparation method provided by the invention has the advantages of simple and convenient operation, high yield and high isomer chiral purity.

Industrial preparation method of 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane

The invention discloses an industrial preparation method of 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane. The industrial preparation method of the 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane comprises the steps that (1) carboxylic acid monoglyceride is prepared by esterification reaction, specifically, glycerol and carboxylic acid are used as raw materials, and under the condition of acidic catalyst,the dehydration reaction is carried out under the condition of 90-150 DEG C for 0.5-4h to obtain the carboxylic acid monoglyceride; (2) ketal cyclization reaction is carried out, specifically, the carboxylic acid monoglyceride and acetone are controlled to perform the cyclization reaction at 20-50 DEG C for 0.5-3 h under the condition of acid catalyst reaction to obtain a cyclization intermediateproduct; and (3) hydrolysis reaction is carried out, specifically, the intermediate product obtained in the step (2) is added into an alkaline solution, the mixture reacts for 0.5-1 h at 20-50 DEG C,and the 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane is obtained. The industrial preparation method of the 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane has the characteristics of green and environment-friendly process, high selectivity of industrial reaction and high conversion rate of raw materials.

Utilization of hexabromoacetone for protection of alcohols and aldehydes and deprotection of acetals, ketals, and oximes under UV irradiation

Hexabromoacetone (HBA) was efficiently used for the protection of alcohols and aldehydes and deprotection of benzaldehyde dimethyl acetal, solketal, and other acetals and ketals. In only 10?min, the protection of glycerol yielded 90% of solketal and protection of benzaldehyde gave 95% of benzaldehyde dimethyl acetal. The deprotection of benzaldehyde dimethyl acetal under UV irradiation gave over 90% yield of benzaldehyde within 15?s using only 2.5?mol% of HBA. HBA was also successfully used for deoximation. Solvent was found to play an important role in the efficiency of HBA for these reactions.

ANTIBACTERIAL COMPOSITION INCLUDING BENZOIC ACID ESTER AND METHODS OF INHIBITING BACTERIAL GROWTH UTILIZING THE SAME

Antibacterial compositions and methods for inhibiting bacterial growth are disclosed. The antibacterial compositions can include a carrier and an antibacterial agent including a benzoic acid ester. The benzoic acid ester can have a carbon chain having a length of two to ten. The benzoic acid ester can have a hydroxyl group on the carbon chain.

Selective functionalization of the primary hydroxy group in triols

A procedure was suggested for preparing functionally substituted 1,2-diols by O-alkylation of hydroxyalkyl-1,3-dioxacyclanes with alkyl halides, followed by acid hydrolysis. The conditions for selective cleavage of the ethers obtained were found. (2,2-Dimethyl-1,3-dioxolan-4-yl)methyl benzoate under the conditions of acid deacetalization undergoes saponification of the ester group.

PROCESS FOR THE MANUFACTURE OF CIS(-)-LAMIVUDINE

An improved process for the manufacture of Lamivudine. The process involves: (a) resolution of racemic lamivudine (intermediate of formula IX) to cis (±) lamivudine of formula (XII) by forming a crystalline salt and separating the product from an organic solvent by fractional crystallization; (b) resolution of cis (±) lamivudine to cis (?) isomer involving formation of S-Binol adduct of formula XIV.

Transesterification catalyzed by iron(III) β-diketonate species

A practical and clean protocol for transesterification catalyzed by a 5 mol % cheap, non-toxic and moisture stable Fe(acac)3 or other iron(III) β-diketonate species in solvent, such as heptane under azeotropic condition is developed. A remarkable rate enhancement was observed upon the addition of 5 mol % of an inorganic base, such as Na2CO3, which suggests that faster formation of a dimeric μ-alkoxy-bridged iron(III) species under alkaline conditions facilitates catalytic turnover. This system provides smooth transesterification over a wide range of structurally diverse esters and alcohols without disturbing functional groups. In addition, the use of iron β-diketonate complexes as catalysts is more environmentally friendly, safer, and economical than other transition-metal catalysts. Preliminary mechanistic studies indicate that the active catalyst is likely a dimeric μ-alkoxy-bridged iron(III) species, as determined by X-ray crystallography of [Fe(dbm)2(O-n-Bu)]2 derived from the alcoholysis of Fe(dbm)3 under alkaline conditions.

Synthesis of aminopropyl phosphonate nucleosides with purine and pyrimidine bases

The synthesis and antiviral evaluation of new acyclic phosphonate nucleosides related to HPMPC (Cidofovir) has been described. These aminopropyl phosphonate nucleosides 1-3 have an amino function within either the acyclic chain (series 2 and 3) or as subs